Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer.
暂无分享,去创建一个
S. Larson | R. Tuttle | R. Grewal | L. Boucai | R. Padovani | Laura Boucai
[1] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[2] M. McBride,et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. , 2006, The Journal of clinical endocrinology and metabolism.
[3] R. Kloos,et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.
[4] O. Schober,et al. [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia]. , 1987, Strahlentherapie und Onkologie (Print).
[5] C. Harmer,et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer , 2002, Postgraduate medical journal.
[6] P. Hall,et al. Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.
[7] D. van Nostrand,et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[8] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] C. Edmonds,et al. The long-term hazards of the treatment of thyroid cancer with radioiodine. , 1986, The British journal of radiology.
[10] M. Schlumberger,et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. , 1997, British Journal of Cancer.
[11] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[12] J. Jonklaas,et al. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. , 2012, Thyroid : official journal of the American Thyroid Association.
[13] S. Larson,et al. Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH , 2011, The Journal of clinical endocrinology and metabolism.
[14] Haynie Tp,et al. Hematologic changes observed following I-131 therapy for thyroid carcinoma. , 1963 .
[15] S. Larson,et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. , 2009, Thyroid : official journal of the American Thyroid Association.
[16] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[17] S. Larson,et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] M. Wichers,et al. Testicular function after radioiodine therapy for thyroid carcinoma , 2000, European Journal of Nuclear Medicine.
[19] C. Glanzmann. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. , 1992, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[20] Anne Hoekstra,et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] H. Brincker,et al. Induction of Leukaemia by 131I Treatment of Thyroid Carcinoma , 1973, British Journal of Cancer.
[22] C. Gwede,et al. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. , 2001, International journal of radiation oncology, biology, physics.
[23] C. Kirsch,et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] S. Purisch,et al. Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.